One-Year Outcomes With Intracoronary Abciximab Evaluated in Diabetic Patients Undergoing Primary PCI
August 16, 2016—In diabetic patients with ST-segment elevation myocardial infarction (STEMI), the administration of intracoronary abciximab—compared with the intravenous bolus—improved the effectiveness of primary percutaneous coronary intervention (PCI) at 1 year, concluded Raffaele Piccolo, MD, et al in a study published in Journal of the American College of Cardiology (JACC.
